• SpyGlass Pharma’s third-quarter 2026 net loss more than doubled year over year to $24.25 million.
• General and administrative expenses rose to $16.21 million due to higher professional service fees and personnel costs.
• Cash, cash equivalents and short-term investments totaled $215.8 million at September 30, expected to fund planned operations through 2028.
• The October acquisition of Advanced Vision Science for approximately $13 million secured scalable commercial intraocular lens manufacturing capacity.
• Enrollment in the BIM-IOL System’s registrational Phase 3 trials remains on track for completion in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyglass Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611111605PRIMZONEFULLFEED9871741) on November 11, 2026, and is solely responsible for the information contained therein.